TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00824785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin, oxaliplatin, capecitabine (EOX)
Description: epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EOX + panitumumab
Description: epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
Study: NCT00336921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin
Description: Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT01275053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leptin
Description: 0.01mg/kg
Study: NCT03990025

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Linked Color Imaging
Description: Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Linked Color Imaging
Description: Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: White Light Imaging
Description: White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: White Light Imaging
Description: White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.
Study: NCT03781960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered at a dose of 480mg IV every 28 days. Treatment with nivolumab will begin after an initial 7-day treatment period with abemaciclib monotherapy.
Study: NCT01492309

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Magnetic Simulation
Description: Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
Study: NCT03395171

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Supplementation of subjects who meet the inclusion criteria and test to have below the threshold of vitamin D in their blood.
Study: NCT01147731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: warfarin plus albiglutide
Description: A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
Study: NCT01963117

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Combined hyperthermia and radiation therapy
Study: NCT01588197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention/Distraction Strategy
Description: One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention/Distraction Strategy
Description: One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
Study: NCT03505671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01242059

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yellow pea protein
Description: Served in a tomato soup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yellow pea protein
Description: Served in a tomato soup

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yellow pea fiber
Description: Served in a tomato soup

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yellow pea fiber
Description: Served in a tomato soup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Served in a tomato soup
Study: NCT00253500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg in a syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: 120 MG q 2 weeks for 4 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: to remove small piece of cancer
Study: NCT02038829

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN101 3 mcg
Description: SUN-101 3 mcg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 6.25 mcg
Description: SUN-101 6.25 mcg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 12.5 mcg
Description: SUN-101 12.5 mcg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 50 mcg
Description: SUN-101 50 mcg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium
Description: Aclidinium 400 mcg bid
Study: NCT01151696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atarax (Hydroxyzine)
Description: One milligram per 10 kilogram, intramuscular use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01588197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Quality/Severity Strategy
Description: One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Quality/Severity Strategy
Description: One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Strategy
Description: One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Strategy
Description: One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
Study: NCT03621969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exam and medical history
Description: This will be completed by a medical doctor on the research team

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exam and medical history
Description: This will be completed by a medical doctor on the research team

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessments
Description: One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessments
Description: One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Instruction and use of Device (RePlay)
Description: 1. providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~2. improving assessment and evaluation of patients involved in future interventional studies,~3. producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Instruction and use of Device (RePlay)
Description: 1. providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~2. improving assessment and evaluation of patients involved in future interventional studies,~3. producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home.
Study: NCT01995370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
Study: NCT01671085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SQ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ
Study: NCT04542798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency COSMAN
Description: Radiofrequency ablation and neuromodulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency COSMAN
Description: Radiofrequency ablation and neuromodulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency COSMAN
Description: Radiofrequency ablation and neuromodulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency COSMAN
Description: Radiofrequency ablation and neuromodulation
Study: NCT01392989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIK cells
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 5 mg/kg, po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 7.5 mg/kg, IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Study: NCT00722436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 100 mg/kg load, then 10 mg/kg/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Placebo
Study: NCT04517526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT
Description: pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles after informed consent, followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of what the investigator considers to be treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites.
Study: NCT01818791

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Making Proud Choices
Description: Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Proud Choices
Description: Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Proud Choices AND Getting To Outcomes
Description: In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality-i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors.
Study: NCT00893113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Alfuzosin-matched One tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alfuzosin-matched One tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: 10 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alfuzosin
Description: 10 mg once daily
Study: NCT00783705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inositol
Description: Given orally
Study: NCT00945750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine FCT
Description: Famotidine 20 mg oral film-coated tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine FCT
Description: Famotidine 20 mg oral film-coated tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine FCT
Description: Famotidine 20 mg oral film-coated tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine FCT
Description: Famotidine 20 mg oral film-coated tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine FCT
Description: Famotidine 20 mg oral film-coated tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine FCT
Description: Famotidine 20 mg oral film-coated tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine CT
Description: Famotidine 20 mg oral chewable tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine CT
Description: Famotidine 20 mg oral chewable tablet taken once daily
Study: NCT02301585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Leg Raising Test
Description: Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients are treated according to Surviving Sepsis Guidelines
Study: NCT03654027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Docetaxel
Description: Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (75mg/m2 IV d1)
Study: NCT00000434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Strong!
Description: Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
Study: NCT03261180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive regular diet
Study: NCT00945750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine CT
Description: Famotidine 20 mg oral chewable tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine CT
Description: Famotidine 20 mg oral chewable tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine CT
Description: Famotidine 20 mg oral chewable tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine CT
Description: Famotidine 20 mg oral chewable tablet taken once daily
Study: NCT05762744

Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide Injection
Description: Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.

Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide Injection
Description: Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.

Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide Injection
Description: Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline injection
Description: Nurses administered saline (0.2 mL) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline injection
Description: Nurses administered saline (0.2 mL) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline injection
Description: Nurses administered saline (0.2 mL) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.
Study: NCT02961205

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation
Description: Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge.
Study: NCT01083797

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: 1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1

Intervention type: DRUG
Group type: OTHER
Intervention: Chloral Hydrate
Description: Initial dose=50 mg/kg
Study: NCT06348277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness plus mood monitoring
Description: mobile app that provides guided mindfulness exercises in addition to prompting for mood monitoring three times per day
Study: NCT04221074

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS II versus ESP
Description: compare between :ultrasound guided Pectoralis nerve(pecs) II block or erector spinae plane (ESP) block in surgical treatment for gynecomastia patients under general anaesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS II versus ESP
Description: compare between :ultrasound guided Pectoralis nerve(pecs) II block or erector spinae plane (ESP) block in surgical treatment for gynecomastia patients under general anaesthesia.
Study: NCT03285880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Napping
Description: Children nap during the nap opportunity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Napping
Description: Children nap during the nap opportunity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Napping
Description: Children nap during the nap opportunity
Study: NCT06348277

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood monitoring
Description: mobile app that prompts for mood monitoring three times per day
Study: NCT01102127

Intervention type: DEVICE
Intervention: Elastography
Description: Performance of US, elastography and FNA.
Study: NCT01286805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Plexus Blockade
Description: The lumbar plexus block will be dosed with 30 milliliters of 0.25% bupivacaine with 1:200,000 epinephrine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will receive only a combined spinal-epidural.
Study: NCT02161549

Intervention type: DEVICE
Intervention: Motus Gl CleanUp System

Intervention type: DEVICE
Intervention: Motus Gl CleanUp System
Study: NCT03402867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep dry needling
Description: Insertion of a filiform needle in the active trigger point of musculoskeletal muscle
Study: NCT03527056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: This is a parallel arm study. All participants in the experimental arm will receive a single fecal transplantation via oral capsules to determine effectiveness and safety in decolonizing gastrointestinal CRE.